

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> <b>A61K 9/08, 37/36</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 94/15584</b> <b>(43) International Publication Date:</b> <b>21 July 1994 (21.07.94)</b>
<b>(21) International Application Number:</b> PCT/SE94/00010 <b>(22) International Filing Date:</b> 10 January 1994 (10.01.94)  <b>(30) Priority Data:</b> 9300105-5                      15 January 1993 (15.01.93)                      SE  <b>(71) Applicant (for all designated States except US):</b> PHARMACIA AB [SE/SE]; S-171 97 Stockholm (SE).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> FLORIN-ROBERTSSON, Ebba [SE/SE]; Norrtullsgatan 12 E, S-113 27 Stockholm (SE). FRANSSON, Jonas [SE/SE]; Torkelsgatan 14 B, S-753 29 Uppsala (SE). MOORE, Diane [US/SE]; Hasselgatan 102 A, S-194 37 Upplands Väsby (SE).  <b>(74) Agents:</b> TANNERFELDT, Agneta et al.; Pharmacia AB, S-112 87 Stockholm (SE).		<b>(81) Designated States:</b> AU, CA, JP, NZ, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i> <i>With amended claims.</i>

**(54) Title:** SOLUTION CONTAINING IGF-1**(57) Abstract**

The invention relates to solutions containing IGF-1 or any functional analogue thereof in which pH is 5.5 to 6.5, preferably 5.7 to 6.2. The amount of phosphate as buffer substance should be in a concentration of less than 50 mmol/L. Preferably the formulation is an aqueous solution of IGF-1 and phosphate as buffer substance in a concentration of 5 to 50 mmol/L or more preferably 5-20 mmol/L, e.g. 10 mmol/L. The solution should be isotonic. The solution gives a reduced pain upon subcutaneous injection. The invention also relates to a process for preparation of the formulation by mixing IGF-1 or any functional analogue thereof with a buffer substance giving pH 5.5 to 6.5 and an isotonic agent. It also relates to a method for treatment of a patient in need of IGF-1 or any functional analogue thereof by administering the claimed formulation.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

5

## SOLUTION CONTAINING IGF-I

The present invention relates to a stable solution containing Insulin-like Growth factor I (IGF-1) in a phosphate buffer in an amount of 50 mmol or less, giving a pH of 5.5 to 6.5, which is isotonic and suitable for injection.

Introduction

15 Insulin-like Growth Factor I (IGF-I) is a peptide present in plasma and other body fluids as well as many cells/tissues. It comprises 70 amino acids, including 3 disulphide bonds, and can stimulate proliferation of a wide range of cell types and it mediates some of the effects of growth hormone. Human IGF-I has been purified from plasma and its complete amino acid sequence is established. (Rinderknecht E et al. "The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin" J. Biol. Chem 253; 2769-76, 1978) Sequences with extensive homologies to human IGF-I are present in IGF-I purified from plasma of other species.

25 It has both systemic and local effects and appears mostly associated with different specific binding proteins, four of which have been sequenced and are termed IGFBP1, IGFBP2, IGFBP3 and IGFBP4. These appear to modulate the biological functions and availability of IGF-I in both a positive and negative manner.

30 Analogues with changed affinities for the binding proteins have been produced and changes of biological activities related to sequence variation have been found. IGF-I appears to act mainly by interactions with the IGF-type 1 receptor exposed on the outer surface of plasma membranes in many different cell types.

35 However, binding to IGF type 2- and insulin receptors also seems to be of importance.

Because of the scarcity of purified plasma IGF-I there was a great necessity to develop methodology for the commercial scale production of IGF-I. Nowadays, such large scale production can readily be achieved by using recombinant DNA techniques.

5 As a result of studies with preparations of recombinant DNA IGF-I it has been demonstrated that it promotes skeletal growth and skeletal muscle protein synthesis. IGF-I has been shown to act both as an endocrine factor as well as a paracrine/autocrine factor. (Skottner et al, Endocrinology, Vol. 124, No 5, 1989 and Cook et al, J Clin Invest 81; 10 206-212; 1988)

Moreover, IGF-I is also effective for the treatment or prevention of catabolic states in patients (Swedish patent application SE 9002731-9) and improves the regeneration of transected peripheral nerves (EP 0 308 386).

15 It has previously been demonstrated *in vitro* that IGF-I also can promote actin synthesis in myocytes in culture (Florini, J R, Muscle and Nerve 10 (1987) 577-598 and contractility of neonatal rat cardiocytes *in vitro* (Vetter, U et al., Basic Res. Cardiol. 83 (1988)647-654).

20 The stability of proteins is generally a problem in the pharmaceutical industry.

A formulation with a low amount of protein will generally lose activity during purification, sterile manufacturing, storage and during the 25 administration.

It has often been solved by drying of the protein in different drying processes, such as freeze-drying. The protein has thereafter been distributed and stored in dried form. The patient necessarily has to reconstitute the dried protein in a solvent before use, which of course 30 is a disadvantage and is an inconvenience for the patient.

For a patient, who needs daily injections of IGF-I, and especially when the patient is a child, it is of importance that the product is easy to handle, to dose and inject. The reconstitution of a freeze-dried product demands prudence and carefulness and should therefore preferably be 35 avoided.

The freeze-drying process is also a costly and time consuming process step, and it would be of great advantage if this step could be avoided, when preparing a commercial product of a protein.

- 5 Another possibility is to add human albumin, which generally reduces the activity loss of the active protein considerably. If the protein is freeze-dried, human albumin functions as a general stabilizer during the purification, sterile manufacture and freeze-drying. It is, however, not desirable to add any substance derived from blood, because of a risk  
10 of virus contamination of plasma, unless it is absolutely necessary.

It would facilitate the use of a pharmaceutical protein if it can be produced and distributed as a stable solution with a prolonged storage life to the patient, who could inject the medicament directly without  
15 reconstitution.

Several solutions have been proposed for the stabilization of different proteins:

- 20 EP 35 204 (Cutter) discloses a method for imparting thermal stability to a protein composition in the presence of a polyol.

EP 381 345 (Corint) discloses an aqueous liquid of a peptide, desmopressin, in the presence of carboxymethylcellulose.

- 25 In WO 89/09614 (Genentech), a stabilized formulation of human growth hormone containing glycine, mannitol, optionally a non-ionic surfactant and a buffer at pH 4-8 is disclosed. The non-ionic surfactant is added for reduced aggregation and denaturation. The formulation has an  
30 increased stability in lyophilized form and as a solution obtained after reconstitution.

- EP 303 746 (International Minerals and Chemical corporation)  
discloses growth hormone (GH) stabilized in aqueous environment by  
35 mixing the growth hormone with polyol, amino acid, polymer of amino acid or choline derivative.

US 4 165 370 (Coval) discloses a gamma globulin solution and a process for the preparation thereof. The solutions contains polyethylene glycol (PEG).

5 In EP 77 870 (Green Cross) the addition of amino acids, monosaccharides, oligosaccharides or sugar alcohols or hydrocarbon carboxylic acid to improve stability of a solution containing factor VIII is disclosed.

10 EP 440 989 (FUJISAWA) discloses a method for preparing a dried composition of IGF-I, which comprises drying a solution containing IGF-I together with a strong acid.

IGF-I in a citrate buffer at pH 6 is known from WO 91/18621, Genentech. Nothing is mentioned regarding stability of IGF-I.

15 Proteins are different with regard to physiological properties. When preparing a pharmaceutical preparation which should be physiologically acceptable, and stable for a long time, consideration can not only be taken to the physiological properties of the protein but also other  
20 aspects must be considered such as the industrial manufacture, easy handling for the patient and safety for the patient. The results of these aspects are not predictable when testing different formulations and each protein has often a unique solution regarding stability.

25 It would facilitate the use of IGF-I if the protein could be produced and distributed as a solution to the patient, who could inject the medicament directly without reconstitution. The solution must be stable for at least two years and it would be advantageous if the final  
30 pharmaceutical solution only contained a minimum of additives, such as sugars, tensides etc.

For solutions intended for subcutaneous injection, pain can be a problem, especially if the pH of the solution deviates from the physiological pH. For stability reason of the active substance it can still  
35 be necessary to choose a pH deviating from the physiological pH. For such solution, a mean to overcome the pain upon injection would be most

important, especially of the drug is to be injected regularly for many years, e.g. IGF-I.

pH is of importance and normally a pH 7 is chosen for solutions to be injected, as this is the physiological pH. Subcutaneous

5 injections of preparations with pH 6 often induce pain.

It is known (J.C. Fleishaker et al. J Clin Pharmacol 1993:33; 182-190) that a saline solution give less pain than citrate buffer or a

citrate buffer containing a drug (here Tiralazad Mesylate). L.A.M.

10 Frenken et al. in BMJ Vol 303, 3 Aug; 1991, reported a study which showed that EPO in a buffer of albumin and citrate, gave more pain than EPO in phosphate buffer of the same pH.

The problem to find a stable solution for IGF-I which does not hurt when injected has not until now been resolved.

15 It has now been found that the pain is significantly reduced when a solution according to the invention is used.

It is in fact so, that the pain felt is the same as when an isotonic aqueous sodium chloride solution is injected subcutaneously.

20 We have thus found a new formulation which solves the above mentioned problems.

We have found that the stability for IGF-I in solution is not so good at pH 7 but that pH 6 gives a better stability. For storage at room temperature, the choice of pH is more important than at 5°C and pH

25 must be less than 7.

We have also found that the stability when using citrate or phosphate as buffer is the same. Compare examples 5 and 6.

30 In our pain study (Example 10) is shown that pH 7 gives less pain (as expected), but our stability studies show that the stability is not good enough at pH 7. By using pH 6 and a low amount of buffer (below 50 mmol) the pain is as low as when using pH 7.

This is a surprising finding.

35 As it is known that citrate buffer can give pain when injected, we have chosen phosphate as the preferred buffer and thereby found a new composition which is stable at 5°C for 24 months and which

does not give pain to the patient and which has a better stability at 30°C than expected.

- 5 A stable solution of IGF-I, only containing a buffer and a salt for providing isotonicity is not known and it must be regarded as surprising, when studying the prior art, that such a solution is stable for two years without any other additional components and also well tolerated by the patient.

10

The following figures are annexed:

- Fig. 1a and 1b. Percentage of remaining concentration of IGF-I at different pH after storage at 5°C and 30°C, respectively during 10 weeks storage. Ex 3
- 15 Fig 2a and 2b. Percentage of remaining concentration of IGF-I at different pH after storage at 5°C and 30°C, respectively during 5 months storage. Ex 4

## 20 The invention

The invention relates to a stable solution containing IGF-I or any functional analogue thereof and a phosphate buffer in an amount of 50 mmol or less, giving a pH of 5.5 to 6.5, preferably 5.7 - 6.2 in an isotonic solution for injection.

25 The claimed solution in which the amount of phosphate buffer is 5-20 mmol/L, preferably around 10 mmol/L gives a reduced pain upon subcutaneous injection in comparison to a composition comprising a higher amount of phosphate.

30 The claimed solution has a remaining activity of at least 90% of its residual original value after  $+5\pm 3^\circ\text{C}$  storage for at least 24 months.

The solution could contain IGF-I, a buffer and an isotonic agent and optionally a preservative. There is thus no need for other

35 stabilizing agents.



The amount of the phosphate buffer is normally in an amount of 5-50 mmol/L, preferably 5-20 mmol/L and more preferably around 10 mmol/L.

The solution has preferably 10 mmol/L sodium phosphate buffer and the pH is 5.7-6.2.

The solution should be isotonic, which could easily be made by any of several excipients known for a person skilled in the art. E.g. NaCl, glycin, mannitol, glycerol and/or other carbohydrates can be added.

Benzyl alcohol could be chosen as preservative.

The invention also relates to a process for preparation of the formulation by mixing IGF-I or any functional analogue thereof with a phosphate buffer substance providing a pH of 5.5 to 6.5 and an isotonic agent and optionally a preservative. It also relates to a method for treatment of a patient in need of IGF-I or any functional analogue thereof by administering the claimed formulation.

By Insulin-like Growth Factor (IGF-I) is meant both naturally occurring human and animal IGF-I and recombinant IGF-I (rIGF-I), such as rhIGF-I (human), rbIGF-I (bovine) and rpIGF-I (porcine). By functional analogues are meant compounds having the same therapeutic effect as IGF-I in animals and humans.

The concentration of IGF-I is only dependent of its solubility in the used buffer and the desired therapeutically amount for the given dose. Preferably the concentration of IGF-I is 1-100 mg/ml and more preferably 1-20 mg/ml.

### EXAMPLES

The recombinant human IGF-I (rhIGF-I) used in the experiments was produced in yeast. rhIGF-I was initially synthesised as a hybrid protein fused to the yeast  $\alpha$ -mating factor pre-pro leader peptide. After expression the primary translation product was secreted out of the cell. During this process the pre-pro-leader was cleaved off. Correctly processed and secreted rhIGF-I could then be isolated from the fermentation media in its native form.

The media with rhIGF-I was then micro filtered and impurities were removed by several chromatographic techniques known within the field.

5

All buffer components used in the examples fulfil the requirements prescribed in Ph. Eur. 2nd Ed.

10

In the examples 1, 2, 5 and 8 lyophilized IGF-I pools from the final step in the purification process were dissolved in the formulation buffer and chromatographed on a Sephadex G-50 column.

15

In the examples 3 and 4 lyophilized IGF-I pools from the final step in the purification process were dissolved in the formulation buffer.

20

In the examples 6, 7 and 9 solutions of IGF-I pools from the final step in the purification process were ultrafiltered to obtain a correct concentration and the correct buffer formulation.

The samples were stored at  $+5\pm 3^{\circ}\text{C}$  or  $+30\pm 3^{\circ}\text{C}$ .

The following analytical techniques were used in all examples:

25

*Reversed Phase HPLC (RP-HPLC)* The elution system is composed of acetonitrile, water, phosphate buffer and propane sulphonic acid sodium salt. Elution is accomplished by decreasing the polarity of the mobile phase. UV detection at 220 nm. Used for measurement of concentration and purity of IGF-I.

30

*SDS-PAGE.* Protein preparations of IGF-I were denaturated by sodium dodecyl sulphate (SDS) to yield negatively charged complexes of protein-SDS. The samples were reduced with 2-mercaptoethanol. Separation was obtained according to molecular

35

size by electrophoresis in polyacrylamide gels (PAGE) in the presence of SDS. After electrophoresis the proteins in the gel were fixed and stained with silver. The evaluation of the gel was done

semi-quantitatively and qualitatively by comparing the samples with standards and reference. Used for detection of IGF-I dimers, polymers or fragments.

- 5 *RRA*. Radioreceptorassay is carried out essentially according to K Hall et al, J. Clin. Endocrin. Metab. 39, 973-76 (1974). Crude membrane fractions were prepared from human placenta. Incubation is performed at +4°C. After incubation *RRA* buffer is added to tubes which are centrifuged.
- 10 All tubes are counted in a gamma counter. Bound/total radioactivity is calculated, as well as bound/total bound radioactivity. The standard curve is drawn and the concentration of IGF-I in the unknown samples is calculated.
- 15 *pH* was carried out as prescribed in Ph. Eur. 2nd Ed.

The reference samples formulations for examples 3 and 4 were stored at -70°C and thawed when the analyses were performed.

20 Example 1.

This example presents the results from a stability study of a solution which has been stored at +5 and +30°C.

Composition per mL:

25	IGF-I	1 mg
	Sodium dihydrogen phosphate	5.25 mg
	Disodium phosphate	0.89 mg
	Sodium chloride	6.43 mg
30	Water for injection	to make 1.0 ml
	pH	5.9

- This composition gives a concentration of 1 mg/mL IGF-I in 50 mmol/L sodium phosphate buffer, and a pH 6, with 10 mmol/L sodium chloride as tonicity adjuster.
- 35 4 mL of this solution was filled in a sterile 5 mL glass ampoule.

10

All samples were stored protected from light and investigated after 12, and 24 months at +5 +/-3°C and after 3, and 12 months at +30 +/-3°C

- 5 RESULTS. The results after storage at +5 and +30°C are presented in tables 1a and 1b respectively.

Table 1a. 1 mg/ml IGF-I stored at +5°C

10	TIME months	RP-HPLC mg/ml	RP-HPLC % of orig. conc.	RP-HPLC purity %
	0	0.99		99.0
	12	0.94	95	97.6
	24	0.93	94	97.7

15

Table 1b 1 mg/ml IGF-I stored at +30°C

20	TIME months	RP-HPLC mg/ml	RP-HPLC % of orig. conc.	RP-HPLC purity %
	0	0.99		99.0
	3	0.85	86	88.5
	12	0.68	69	72.4

25

#### RP-HPLC

After 24 months of storage at +5°C 94 % of the original concentration remained.

30

At +30°C 86 % of IGF-I remained after 3 months.

#### CONCLUSION

- 35 This study shows that storage at +5°C for 24 months does not largely influence the quality of the product.

Example 2

- 5 The purpose of this study was to compare the stability of IGF-I formulated in an aqueous solution with 10 or 50 mmol/L phosphate buffer, pH 6.

Composition 2A:

10

1 mL contains:

IGF-I	2 mg
Sodium dihydrogen phosphate	5.25 mg
15 Disodium phosphate	0.89 mg
Sodium chloride	6.43 mg
Water for injection	to make 1.0 ml
pH	5.9

- 20 The concentration of the buffer is 50 mmol/L.

Composition 2B:

1 ml contains:

25

IGF-I	1.7 mg
Sodium dihydrogen phosphate	1.02 mg
Disodium phosphate	0.21 mg
Sodium chloride	8.48 mg
30 Water for injection	to make 1.0 ml
pH	6.0

The concentration of the buffer is 10 mmol/L.

35

## RESULTS

The results of analysis of IGF-I in the formulation with 50 mmol/L phosphate buffer are presented in tables 2a-b and the results for IGF-I in 10 mmol/L phosphate in tables 2c-d.

Table 2a. Composition 2A stored at +5°C

TIME months	RP-HPLC mg/ml	RP-HPLC % of orig. conc.	RP-HPLC purity %
0	2.1	-	99.8
12	2.0	95	98.5
24	2.0	95	97.8

Table 2b Composition 2A stored at +30°C

TIME months	RP-HPLC mg/ml	RP-HPLC % of orig. conc.	RP-HPLC purity %
0	2.1		99.8
3	1.8	86	88.0
9	1.4	67	73.5

Table 2c Composition 2B stored at +5°C

TIME months	RP-HPLC mg/ml	RP-HPLC % of orig. conc.	RP-HPLC purity %
0	1.7		99.6
12	1.7	100	98.2
24	1.7	100	97.7

Table 2d Composition 2B stored at +30°C

TIME months	RP-HPLC mg/ml	RP-HPLC % of orig. conc.	RP-HPLC purity %
0	1.7		99.6
3	1.5	88	87.7
9	1.2	71	73.9

10

From the data in the tables it can be noted that there were no significant differences in stability of IGF-I in the two investigated formulations.

15

Analysis by SDS-PAGE could not detect any differences in stability between the two formulations.

The buffer capacity of a 10 mmol/L phosphate buffer has proven to be sufficient to maintain a stable pH of the formulation.

20

New clinical data has indicated that a phosphate buffer concentration of 10 mmol/L would be tolerated better by patients receiving subcutaneous injections.

25

### CONCLUSION

The stability of IGF-I 2 mg/ml formulated in 10 mmol/L phosphate buffer, pH 6, is the same as in 50 mmol/L phosphate buffer.

30

IGF-I 2 mg/ml formulated in 10 mmol/L phosphate buffer, pH 6, was found to be stable for 24 months when stored at  $+5 \pm 3^\circ\text{C}$ .

### Example 3

35

The purpose of this experiment was to study the influence of pH on the stability of IGF-I in simple buffer solutions. Pharmaceutical use of IGF-I necessitates isotonic solutions, and sodium chloride

was chosen as the tonicity agent. A wide pH range was chosen for this experiment, partly to provoke changes at the extreme ends (pH 3 and 9) and partly to cover the pharmacological pH range, in this case pH 5 and 7.

5

For comparison, IGF-I in the same buffer solutions but without sodium chloride were included in this study. E - H are thus not isotonic. The reason for this was to investigate if the sodium chloride affected the stability of IGF-I.

10

#### EXPERIMENTAL METHOD

Solutions containing 750 µg/ml of IGF-I were prepared in the following buffers:

15	A:	50 mmol/L sodium citrate 95 mmol/L sodium chloride	pH = 3
20	B:	50 mmol/L sodium acetate 95 mmol/L sodium chloride	pH = 5
25	C:	50 mmol/L sodium phosphate 95 mmol/L sodium chloride	pH = 7
	D:	50 mmol/L glycine 95 mmol/L sodium chloride	pH = 9
30	E:	50 mmol/L sodium citrate	pH = 3
	F:	50 mmol/L sodium acetate	pH = 5
35	G:	50 mmol/L sodium phosphate	pH = 7
	H:	50 mmol/L glycine	pH = 9



Storage: 0 (initial samples), 3, 6 and 10 weeks (samples A-D) or 0 and 10 weeks (samples E-H).

5

Temperature: +5°C and +30°C.

## RESULTS

10 RP-HPLC gave the results as given in Figures 1a and 1b. in which the result for A, B, C and D at +5°C and +30°C are shown and calculated as percentage. Similar results were obtained for solutions E-H.

15 The concentration and RRA activity of IGF-I in the buffers with sodium chloride at pH 3, 5 and 7 were stable up to 10 weeks at +5°C. At +30°C, the concentration of IGF-I in glycine buffer (pH = 9) was not stable when analyzed after three weeks. At pH 3, 5 and 7 in the buffers with sodium chloride, the concentration and RRA activity of IGF-I was slightly diminished when stored for 10 weeks  
20 at +30°C. At pH 9, and stored for 10 weeks at +30°C, the IGF-I concentration, receptor activity and immunological activity were greatly reduced. The solutions without sodium chloride were slightly less stable than their isotonic counterparts, according to HPLC, and comparably stable according to RRA.

25

## SDS-PAGE

Changes in the molecular size distribution occurred when IGF-I in buffers A and D (pH 3 and 9 respectively) were stored for 3 weeks at +30°C but there were no changes in buffers B and C (pH 5 and 7  
30 respectively).

## CONCLUSION

The results of this experiment shows that IGF-I is more stable in sodium acetate buffer, pH 5 and in sodium phosphate buffer, pH 7,  
35 than in sodium citrate buffer pH 3 or glycine buffer, pH 9. Also, the results indicate that the presence of sodium chloride has a slightly positive effect on the stability of IGF-I in these buffer solutions.

Example 4

5 According to the results of the study in example 3, IGF-I was more stable at pH 5 and 7 than at pH 3 and 9. Because formulations with a pH as low as pH 5 may cause discomfort when administered subcutaneously or intramuscularly, a pH above 5 should be preferred and the pH range chosen for this experiment was pH 6 to pH 7.5.

10

Solutions of sodium dihydrogen phosphate have buffering capacity in this range and are suitable for parenteral injection when made isotonic. For this reason, sodium phosphate, with addition of either NaCl or glycerol to raise the tonicity, was the buffer used in this

15

study.

The purpose of this preformulation study was to determine if there is an optimal pH for the formulation of IGF-I to make an assessment of the stability of IGF-I in these solutions.

20

EXPERIMENTAL METHOD

Freeze dried IGF-I bulk was dissolved in each of five buffer solutions to a concentration of about 1 mg IGF-I/ml. The buffer

25 solutions were prepared from sodium dihydrogen phosphate and disodium phosphate proportionately to make 50 mmol/L, pH 6, 6.5, 7 and 7.5. Sodium chloride, 100 mmol/L was added to four of the solutions (pH 6-7.5) as a tonicity agent to bring the osmolality to about 290 mmol/L. For comparison glycerol, 200 mmol/L was added

30 instead of sodium chloride to a pH 7 solution. The individual buffer compositions are listed in table 3. The volume of each solution was 125 ml. The five IGF-I solutions were each filtered through a sterile Durapore® filter (Millipore, 47 mm diam., 0.22 µm pore size) and dispensed using a peristaltic pump, (Schuco Peristaltic Filler,

35 Paxall Schubert Machinery Co. A/S) into sterile glass vials to a volume of 1 ml/vial. The vials were stoppered with sterile rubber

17

stoppers and sealed with metal caps. The filled vials were subsequently stored and analyzed.

Table 3

5

Composition per vial and pH of each IGF-I

Solution: labelled DsQ 12	A	B	C	D	E
<u>Ingredient</u>					
IGF-I (freeze-dried powder)	1 mg	1 mg	1 mg	1 mg	1 mg
15 Disodium phosphate, dodecahydrate	2.2 mg	5.6 mg	10.9 mg	15.0 mg	10.9 mg
Sodium dihydrogen phosphate, monohydrate	6.0 mg	4.7 mg	0.3 mg	0.1 mg	0.3 mg
20 Sodium chloride (solutions A-D)	5.8 mg	5.8 mg	5.8 mg	5.8 mg	-
Glycerol	-	-	-	-	18.4 mg
25 Water for injection to make	1 ml	1 ml	1 ml	1 ml	1 ml
-	pH: 6	6.5	7	7.5	7
-					
-					

30

## RESULTS

The results are shown in figures 2a and 2b giving percent of reference value for IGF-I according to RP-HPLC.

- 5 According to the results, at +30°C, IGF-I in sodium phosphate buffer with NaCl is stable at pH 6 and somewhat less stable at pH 6.5 and 7, and much less stable at pH 7.5. Also, the addition of glycerol instead of NaCl decreased the stability of IGF-I.

## 10 CONCLUSION

- In this experiment two conclusions can be made. Firstly, in the range of pH 6 to pH 7.5, IGF-I in isotonic sodium phosphate buffer (with NaCl as tonicity agent) is more stable the lower the pH. i.e. stability decreases with higher pH. Secondly, IGF-I in this isotonic sodium phosphate buffer with NaCl is stable for six months when  
15 stored at +5°C.

## 20 Example 5

The purpose of this study was to investigate the stability of IGF-I, 2 mg/ml in a citrate buffer with pH 6.

1 ml contains:

25	IGF-I	2 mg
	Trisodium citrate, dihydrate	10.5 mg
	Disodium citrate, 1 1/2 hydrate	3.76 mg
	Sodium chloride	4.97 mg
30	Water for injection	to make 1.0 ml
	pH	6.0

- 35 The concentration of the buffer is 50 mmol/L

## RESULTS

Table 4 Stability data for IGF-I

5	Temperature	Time	RP-HPLC	RP-HPLC
	°C	months	concentr mg/mL	purity %
10	+5 °C	0	1.9	98.8
		1.5	2.0	98.0
		26	2.1	97.8
15	30 °C	0	1.9	98.8
		1.5	1.9	93.6

## CONCLUSION

- 20 IGF-I formulated in a citrate buffer with pH 6 was found to be stable for 26 months when stored at +5 °C.

Example 6

25

The purpose of this study was to investigate the stability of IGF-I, 7 mg/ml in a 50 mmol/L phosphate buffer with pH 6.

1 ml contains:

30

IGF-I

7 mg

Monosodium phosphate, anhydrous

5.25 mg

Disodium phosphate, anhydrous

0.89 mg

Sodium chloride

6.43 mg

Water for injection

to make 1.0 ml

35

pH

5.9

## RESULTS

Table 5 Stability data for IGF-I

5	Temperature	Time	RP-HPLC	RP-HPLC	RP-HPLC
	°C	months	concentr of orig conc	conc	purity
			mg/mL	%	%
10	5	0	7.0		99.1
		12	7.3	100	98.2
		18	7.2	100	97.4
10	30	0	7.0		99.1
		3	6.2	89	94.0

## 15 CONCLUSION

IGF-I 7 mg/ml was found to be stable for 18 months at +5°C when formulated in a 50 mmol/L phosphate buffer with pH 5.9.

20 Example 7

The purpose of this study was to investigate the stability of IGF-I, 10 mg/ml in a 10 mmol/L phosphate buffer with pH 6.

1 mL contains:

25

IGF-I	10 mg
Monosodium phosphate, anhydrous	1.02 mg
Disodium phosphate, anhydrous	0.21 mg
Sodium chloride	8.48 mg
30 Water for injection	to make 1.0 ml
pH	6.0

## RESULTS

Table 6 Stability data for IGF-I

5	Temperature	Time	RP-HPLC	RP-HPLC % of orig conc	RP-HPLC purity
	°C	months	mg/ml	%	%
10	5	0	10.8		98.6
		12	10.8	100	97.8
	30	0	10.8		98.6
		3	9.4	92	86.4

15

## CONCLUSION

IGF-I 10 mg/ml was found to be stable for at least 12 months at +5°C when formulated in a 10 mmol/L phosphate buffer with pH 6.

20 EXAMPLE 8

The purpose of this study was to investigate the stability of IGF-I 1.4 mg/ml in a 50 mM phosphate buffer with pH 6. and benzyl alcohol as preservative.

## 25 Formulation 8a.

Composition per ml:

30	IGF-I	1.4 mg
	Monosodium phosphate	5.25 mg
	Disodium phosphate	0.89 mg
	Sodium chloride	6.43 mg
	Benzyl alcohol	11 mg
	Water for injection	up to 1.0 ml
	pH	5.9

35

A nonpreserved reference sample was also prepared, formulation 8b

The cartridges were investigated after 23 months storage at +5 +/-3°C.

5

The results of analysis after storage are presented in table 7

Table 7. 2 mg/ml IGF-I stored at +5°C for 23 months

10	SAMPLE	RP-HPLC mg/ml	RP-HPLC purity %
	Preserved, 8a	1.4	98.2
15	Unpreserved, 8b	1.5	98.5

#### CONCLUSION

20 No significant differences in concentration or purity could be detected after 23 months of storage at +5°C. Benzyl alcohol does not effect the stability of IGF-I. Both formulations were stable during the studied time.

25

#### EXAMPLE 9

30 The purpose of this study was to investigate the stability of IGF-I 9 mg/ml in a 10 mmol/L phosphate buffer with pH 6 and benzyl alcohol.



## Composition per ml:

	IGF-I	9 mg
5	Monosodium phosphate	1.02 mg
	Disodium phosphate	0.21 mg
	Sodium chloride	8.48 mg
	Benzylic alcohol	14 mg
	Water for injection	1.0 ml
10	pH	6.0

The vials were stored and investigated after 6 months at +25 +/- 3°C and +5 +/- 3°C.

15 The results are presented in tables 8a and 8b

Table 8a. 9 mg/ml IGF-I with benzyl alcohol stored at +5°C

20	TIME months	RP-HPLC mg/ml	RP-HPLC purity %
	0	8.9	98.4
	6	8.8	98.0

25

Table 8b. 9 mg/ml IGF-I with benzyl alcohol stored at +25°C

30	TIME months	RP-HPLC mg/mL	RP-HPLC purity %
	0	8.9	98.4
	6	6.8	95.8

35

## CONCLUSION

Only a small decrease in purity could be noticed after 6 months of storage at +5°C. The formulation remained stable during the study.

5 Example 10

The local tolerance at subcutaneous injection of 9 formulations, I-X, was investigated in 10 male subjects,

Ten injections were given on the lower arms to each subject. The injections were given with an interval of 17 minutes/inj/subject.

10 The total dose of rIGHF-I was 3 mg divided into 3 injections with 1 mg IGF-I/injection.

All injections were given within 3.5 hours to each subject, with a volume of 0.2 ml/injection.

15 A sodium chloride composition with physiological pH, composition I, was used as a control.

The injection pain, assessed by the volunteers on a horizontal visual analogue scale (V.A.S.) 0-100 mm, 30 seconds after each injection (0 mm means no pain, 100 mm means severe pain).

20

Compositions used in this study in mg  
Water for injection to 1 ml

	I	II	III	IV	V
IGF-I	-	-	-	5.00	-
25 Monosodium phosphate	-	0.51	1.02	1.02	5.21
Disodium phosphate	-	0.11	0.21	0.21	0.92
mmol/L phosphate	-	5	10	10	50
Sodium chloride	9.0	8.3	8.48	8.48	6.3
pH	7	6	6	6	6
30	<hr/>				
	VI	VII	VIII	IX	
IGF-I	5.00	-	-	5.00	
Monosodium phosphate	5.21	0.54	2.70	2.70	
Disodium phosphate	0.94	0.78	3.91	3.91	
35 mmol/L phosphate	50	10	50	50	
Sodium chloride	6.38	8.37	6.38	6.38	
pH	6	7	7	7	

When LSMEAN on V.A.S. mmol/L was calculated for each composition the following result was obtained:

5	<u>Table 9</u>	
	Composition	LSMEAN
	VIII	6.5
	I	7.2
	IX	8.3
10	III	9.7
	IV	12.2
	II	15.1
	VII	16.3
	V	30.9
15	VI	38.4

#### CONCLUSIONS

Compositions III and IV cause considerably less pain than compositions V and VI.

- 20 At pH 6, a decrease in buffer concentration, results in decreases discomfort at injection and reduces the injection pain to a level comparable to physiological sodium chloride solution.

- 25 This study shows that a decreased buffer concentration at pH 6 is advantageous in order to achieve the best local tolerance on injection of IGF-I.

## CLAIMS

5

1. Stable solution containing IGF-I or any functional analogue thereof and a phosphate buffer in an amount of 50 mmol or less, giving a pH of 5.5 to 6.5, preferably 5.7 - 6.2 in an isotonic solution for injection.
2. Stable solution according to claim 1 in which the amount of phosphate buffer is 5-20 mmol/L, preferably around 10 mmol/L and which gives a reduced pain upon subcutaneous injection in comparison to a composition comprising a higher amount of phosphate.
3. Stable solution according to claim 1 or 2 which after  $+5\pm 3^{\circ}\text{C}$  storage for at least 24 months has a remaining activity of at least 90% of its original value.
4. Stable solution according to any of claims 1 to 3 containing IGF-I, the buffer and an isotonic agent and optionally a preservative.
5. Stable solution according to any of claims 1 to 4 in which the buffer is sodium phosphate buffer.
6. Stable solution according to claim 5 in which the amount of sodium phosphate buffer is 5-50 mmol/L.
7. Stable solution according to any of claims 1 to 6 in which the amount of phosphate buffer is 5-20 mmol/L, preferably around 10 mmol/L.
8. Stable solution according to claim 7 in which the buffer is a 10 mmol/L sodium phosphate buffer and pH is 5.7-6.2.

9. Stable solution according to any of claims 1 to 8 which also contains NaCl.
- 5 10. Stable solution according to any of claims 1 to 9 which contains benzyl alcohol as preservative.
11. Stable solution according to any of claims 1 to 10 which also contains glycine, glycerol, mannitol and/or carbohydrates as isotonic agents.
- 10 12. A process for preparation of the stable solution according to any of claims 1 - 11 by mixing IGF-I or any functional analogue thereof with the buffer substance giving pH 5.5 to 6.5 and an isotonic agent and optionally a preservative.
- 15 13 A method for treatment of a patient in need of IGF-I or any functional analogue thereof by administering the stable solution according to any of claims 1-11.
- 20 14. A method for reducing local irritation and resulting pain from a subcutaneous injection of IGF-I by administering the stable solution according to any of claims 1-11.

## AMENDED CLAIMS

[received by the International Bureau on 10 June 1994 (10.06.94);  
original claim 1 amended; remaining claims unchanged (2 pages)]

5

- 10 1. Stable solution containing IGF-I or any functional analogue thereof and a phosphate buffer in an amount of 50 mmol/L or less, giving a pH of 5.5 to 6.5, preferably 5.7 - 6.2 in an isotonic solution for injection.
- 15 2. Stable solution according to claim 1 in which the amount of phosphate buffer is 5-20 mmol/L, preferably around 10 mmol/L and which gives a reduced pain upon subcutaneous injection in comparison to a composition comprising a higher amount of phosphate.
- 20 3. Stable solution according to claim 1 or 2 which after  $+5\pm 3^{\circ}\text{C}$  storage for at least 24 months has a remaining activity of at least 90% of its original value.
- 25 4. Stable solution according to any of claims 1 to 3 containing IGF-I, the buffer and an isotonic agent and optionally a preservative.
5. Stable solution according to any of claims 1 to 4 in which the buffer is sodium phosphate buffer.
- 30 6. Stable solution according to claim 5 in which the amount of sodium phosphate buffer is 5-50 mmol/L.
- 35 7. Stable solution according to any of claims 1 to 6 in which the amount of phosphate buffer is 5-20 mmol/L, preferably around 10 mmol/L.
8. Stable solution according to claim 7 in which the buffer is a 10 mmol/L sodium phosphate buffer and pH is 5.7-6.2.

9. Stable solution according to any of claims 1 to 8 which also contains NaCl.

5

10. Stable solution according to any of claims 1 to 9 which contains benzyl alcohol as preservative.

10

11. Stable solution according to any of claims 1 to 10 which also contains glycine, glycerol, mannitol and/or carbohydrates as isotonic agents.

15

12. A process for preparation of the stable solution according to any of claims 1 - 11 by mixing IGF-I or any functional analogue thereof with the buffer substance giving pH 5.5 to 6.5 and an isotonic agent and optionally a preservative.

20

13 A method for treatment of a patient in need of IGF-I or any functional analogue thereof by administering the stable solution according to any of claims 1-11.

25

14. A method for reducing local irritation and resulting pain from a subcutaneous injection of IGF-I by administering the stable solution according to any of claims 1-11.

1/2

Fig 1 a. Percentage of remaining concentration of IGF-I at different pH after storage at +5°C.




Fig. 1 b. Percentage of remaining concentration of IGF-I at different pH after storage at +30°C




Figure 1



2/2

Fig 2 a. Percentage of remaining concentration of IGF-I at different pH after storage at +5°C.




Fig 2 b. Percentage of remaining concentration of IGF-I at different pH after storage at +30°C.




Figure 2

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/SE 94/00010

## A. CLASSIFICATION OF SUBJECT MATTER

IPC5: A61K 9/08, A61K 37/36  
According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC5: A61K, C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EMBASE, MEDLINE, WPI, WPIL, CLAIMS, CA

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO, A1, 9118621 (GENENTECH, INC.), 12 December 1991 (12.12.91), page 10, line 5 - page 11, line 19 --	1-12
P,A	EP, A1, 0528313 (BOEHRINGER MANNHEIM GMBH), 24 February 1993 (24.02.93), page 4 lines 25-37; page 5 lines 17-25, lines 45-58; page 6, line 39 - page 7 line 17; page 8 lines 12-17 --	1-12
A	DE, A1, 3939346 (BEHRINGWERKE AG), 6 June 1991 (06.06.91), page 2 lines 1-64 -- -----	1-12

☐ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

\* Special categories of cited documents:

- \* "A" document defining the general state of the art which is not considered to be of particular relevance
- \* "B" earlier document but published on or after the international filing date
- \* "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \* "O" document referring to an oral disclosure, use, exhibition or other means
- \* "P" document published prior to the international filing date but later than the priority date claimed

\* "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\* "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\* "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

\* "&" document member of the same patent family

Date of the actual completion of the international search

14 April 1994

Name and mailing address of the ISA/  
Swedish Patent Office  
S-100 02 STOCKHOLM

Date of mailing of the international search report

14 April 1994

Authorized officer

# INTERNATIONAL SEARCH REPORT

In tional application No.

PCT/SE 94/00010

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 13-14  
because they relate to subject matter not required to be searched by this Authority, namely:

See PCT Rule 39.1(iv): Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.

2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

26/02/94

International application No.  
PCT/SE 94/00010

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO-A1-	9118621	12/12/91	EP-A-	0536226	14/04/93
<hr/>					
EP-A1-	0528313	24/02/93	AU-A-	2409492	16/03/93
			DE-A-	4126983	18/02/93
			WO-A-	9303744	04/03/93
<hr/>					
DE-A1-	3939346	06/06/91	AU-A-	6702990	06/06/91
			CA-A-	2030988	30/05/91
			EP-A-	0430200	05/06/91
<hr/>					